Type 2 Diabetes Remission and Long-Term Microvascular Risk: A Critical Review of Longitudinal Evidence

Abstract

Background/Objectives: Type 2 diabetes (T2D) remission is increasingly attainable, but its implications for long-term microvascular risk remain uncertain. Methods: We critically appraised longitudinal reports relating achieved remission to subsequent kidney, retinal, neurologic, or composite outcomes, distinguishing temporally separated remission–outcome analyses from supportive glycemic trajectory studies with overlapping ascertainment. Evidence was checked through 5 October 2026, with an additional directly relevant CHIA companion report incorporated during revision. Eight reports were appraised (six principal direct longitudinal reports, one supportive trajectory report, and one contextual retinopathy report); overlapping CHIA populations were identified, while Danish participant overlap remains unverified. Heterogeneous exposures and estimands precluded pooling. Results: Across surgical, lifestyle, primary care and pharmacotherapy settings, several studies associated remission with lower subsequent microvascular risk. In the temporally separated CHIA analysis, remission during the first two years was associated with fewer microvascular complications over the following five years (adjusted HR 0.68, 95% CI 0.62–0.74). In Look AHEAD, remission at any assessed visit was associated with lower high-/very-high-risk chronic kidney disease (HR 0.67, 95% CI 0.52–0.87). Trajectory analyses provide complementary but temporally less secure evidence and should not be equated with medication-free remission. Conclusions: Achieved T2D remission is a potentially informative prognostic state; evidence concerning duration is suggestive but definition- and design-dependent. Neither a causal effect of remission itself nor normalization of prior microvascular risk has been established.

1. Introduction

Type 2 diabetes (T2D) has traditionally been conceptualized as a chronic progressive disorder requiring lifelong risk factor management. That model is no longer sufficient. Intensive weight management, metabolic surgery, and increasingly effective glucose- and weight-lowering therapies can produce prolonged periods in which glycemia falls below the diagnostic threshold for diabetes. In the DiRECT trial, remission was achieved in 46% of intervention participants at 12 months and 36% at 24 months, demonstrating that remission can be a realistic therapeutic outcome in selected patients [1,2]. A 2025 systematic review of nonsurgical randomized trials further confirmed that remission can be induced through several multimodal strategies, although definitions and intervention intensity remain heterogeneous [3].

The 2021 international consensus report proposed “remission” as the preferred term and recommended HbA1c < 6.5% (48 mmol/mol) measured at least three months after withdrawal of usual glucose-lowering pharmacotherapy as the usual diagnostic criterion [4]. Importantly, the consensus did not equate remission with cure. It explicitly recognized the possibility of relapse and the persistence of retinopathy, nephropathy, neuropathy, and cardiovascular risk after remission, recommending continued glycemic and complication surveillance [4].

This distinction is central to the present review. A biochemical threshold describes current glycemic status, whereas microvascular complications reflect cumulative exposure, susceptibility, and established organ injury. The legacy effect literature provides a biological and clinical framework for this discrepancy. In UKPDS follow-up, benefits of earlier intensive glycemic control persisted after between-group HbA1c differences disappeared [5]. Contemporary mechanistic work likewise supports persistent cellular and epigenetic consequences of previous metabolic exposure [6,7]. Thus, remission could plausibly lower future microvascular risk without erasing the consequences of prior hyperglycemia.

Most remission research has asked how remission can be achieved. A clinically different question is what remission means after it has occurred. If remission is associated with fewer subsequent complications (and especially if longer remission predicts greater benefit), it may represent more than a biochemical label. Conversely, because remission is achieved rather than randomly assigned, favorable outcomes may partly reflect shorter diabetes duration, greater residual beta-cell function, larger weight loss, lower treatment burden, or healthier behavior.

This review therefore focuses specifically on longitudinal evidence in which achieved T2D remission precedes microvascular outcomes. Our objectives were to assess the consistency and magnitude of the association, examine evidence for a duration–response relationship, distinguish organ-specific from composite outcomes, and define what can (and cannot) be inferred about disease modification.

2. Methods of Evidence Identification and Appraisal

2.1. Review Design and Question

This article was designed as a focused critical review rather than a PRISMA systematic review. Its purpose was interpretive rather than exhaustive: to evaluate the directly relevant longitudinal evidence and its methodological limitations. The review question was as follows: among adults with T2D, is achieved remission, greater remission durability, or a favorable remission-related glycemic trajectory associated with lower subsequent microvascular risk than persistent diabetes or non-remission? Target outcomes were incident CKD/diabetic kidney disease, nephropathy, retinopathy, neuropathy, microangiopathy, or a composite microvascular endpoint.

2.2. Evidence Identification and Eligibility

Evidence identification used targeted PubMed searching and backward and forward citation tracking of longitudinal remission cohorts; the original evidence check extended through 5 October 2026. For reproducibility, the following fully specified PubMed search expression is provided: ((“Diabetes Mellitus, Type 2”[MeSH Terms] OR “type 2 diabetes”[Title/Abstract] OR T2D[Title/Abstract]) AND (remission[Title/Abstract] OR “glycemic remission”[Title/Abstract] OR “glycaemic remission”[Title/Abstract]) AND (microvascular[Title/Abstract] OR nephropathy[Title/Abstract] OR “chronic kidney disease”[Title/Abstract] OR retinopathy[Title/Abstract] OR neuropathy[Title/Abstract] OR microangiopathy[Title/Abstract])). This expression makes the search concepts reproducible; it should not be mistaken for an archived verbatim record of the historical search. The retained search documentation does not establish whether date, language, or publication type limits were applied, so no historical filter settings are asserted. Primary reports were selected for longitudinal relevance, remission ascertainment before subsequent microvascular follow-up, and availability of a relevant effect estimate. Companion publications were identified by cohort name, investigators, setting and sample size and were not counted as independent cohorts. Estimates, definitions, comparators and limitations were cross-checked against the published reports. This was a focused critical review, not a systematic review, and no exhaustive database coverage is claimed.

2.3. Data Interpretation and Decision Not to Pool

Eight reports were appraised: six principal direct longitudinal reports (Coleman [8], Madsen [9], Hounkpatin [10], Gregg [11], Morieri [12], and Fadini [13]), one supportive CHIA glycemic trajectory report (Dambha-Miller [14]), and one contextual Danish retinopathy report [15]. The two CHIA reports [10,14] use a shared primary care data source, and overlapping study populations and must not be counted as independent cohorts. The Danish surgical and retinopathy reports [9,15] address related RYGB settings, but participant-level overlap has not been established from the available descriptions; therefore, no definitive total of independent cohorts is asserted. The retinopathy remission comparison [15] was cross-sectional rather than a further temporally ordered remission outcome analysis. Studies differed in HbA1c thresholds, permitted medication, assessment schedule, follow-up, outcomes, and covariate adjustment. In particular, a visit-based epidemiological remission surrogate is not equivalent to continuous medication-free remission, and sustained subdiabetic glycemia during treatment is not equivalent to consensus-defined remission. A single pooled hazard ratio would therefore combine incompatible estimands. We synthesized evidence qualitatively and appraised, for each report, temporal ordering, confounding, selection/missingness, outcome ascertainment, and death/loss to follow-up. No numerical risk-of-bias score was assigned.

2.4. Causal Framework

Achieved remission is a post-baseline, non-randomized exposure, including when it occurs within a randomized intervention trial. Key threats to causal interpretation include confounding by diabetes duration and severity, baseline HbA1c, residual beta-cell function, adiposity and weight change, treatment selection and response, medication changes, comorbidity burden, socioeconomic and behavioral factors, differential surveillance, and time-related selection. Accordingly, adjusted associations are interpreted primarily as prognostic evidence. Evidence of a duration–response relationship strengthens biological plausibility but does not, by itself, eliminate confounding.

2.5. Use of Generative Artificial Intelligence

During the preparation of this manuscript, the authors occasionally used ChatGPT (GPT-6; OpenAI) as a support tool to review the structure and organization of the text. All suggestions were critically reviewed, supervised, and edited by the authors, who retained full control over the scientific content. Potential limitations, inaccuracies, or biases associated with this tool were considered, and all suggestions were carefully evaluated before incorporation into the manuscript. The authors take full responsibility for the final content of this publication.

3. Direct Longitudinal Evidence

3.1. Bariatric Surgery and the Legacy Effect Hypothesis

Coleman et al. evaluated 4683 adults with T2D after bariatric surgery and incident retinopathy, neuropathy and/or nephropathy [8]. Remission versus never achieving remission was associated with lower adjusted microvascular risk (HR 0.71, 95% CI 0.60–0.85). Separately, among patients who subsequently relapsed, each additional year spent in remission before relapse was associated with lower risk (HR 0.81, 95% CI 0.67–0.99). The latter is a conditional, relapse subgroup association, not the same estimand as the overall remission contrast. Some published sensitivity analyses retained a favorable direction but had confidence intervals including the null. Thus, the observation is compatible with a legacy effect rather than definitive proof of one; differences in disease phenotype, surgery response, weight change and follow-up may explain part of the association.

Madsen et al. examined Roux-en-Y gastric bypass in a Danish population-based matched cohort [9]. Among operated patients, remission at one year versus non-remission was associated with lower subsequent microvascular risk (HR 0.43, 95% CI 0.25–0.72). Importantly, the operational definition included an HbA1c below 6.0% while taking metformin alone as one route to remission; it therefore must not be represented as uniformly medication-free remission. The retinopathy-focused Danish report [15] evaluated remission versus non-remission in a cross-sectional analysis, whereas its longitudinal retinopathy change comparison concerned RYGB-treated patients versus non-operated controls. It is therefore contextual evidence, not another prospective remission-versus-non-remission effect estimate. Although the reports [9,15] concern related Danish surgical settings, individual-level cohort overlap has not been verified and should not be assumed. Comparisons within operated patients should not be conflated with surgery-versus-control comparisons. Additional details on remission definitions, exposure ascertainment, microvascular outcomes, and methodological characteristics of the included studies are provided in Appendix A (Table A1).

3.2. Remission Trajectories in Routine Care

The CHIA evidence requires separation of two complementary analyses. Hounkpatin et al. [10] classified remission during the first two years and then assessed complications during the following five years; remission versus no remission was associated with fewer microvascular complications (adjusted HR 0.68, 95% CI 0.62–0.74). This prespecified temporal separation makes it directly informative for the present review, although residual confounding and routine care outcome ascertainment remain concerns. Dambha-Miller et al. [14] subsequently described seven-year HbA1c trajectories in 60,287 people, reporting lower complication hazards for an initially low then rising trajectory (aHR 0.65, 95% CI 0.61–0.70) and a stable low-HbA1c trajectory (aHR 0.59, 95% CI 0.55–0.64), each compared with persistently high HbA1c. However, trajectory assignment draws on repeated measurements over follow-up and may incorporate observations after complications occurred. Reverse causality, survival/measurement selection and informative follow-up cannot be excluded. Stable low HbA1c also does not necessarily mean sustained medication-free remission. The trajectory report is therefore supportive contextual evidence only, not an independent temporally eligible CHIA cohort or direct proof of remission durability.

3.3. Kidney Outcomes and Remission Durability in Look AHEAD

The Look AHEAD analysis provides comparatively informative kidney-specific evidence [11]. Among 4132 participants in the CKD analysis, remission at any study visit was associated with lower high-/very-high-risk CKD (HR 0.67, 95% CI 0.52–0.87), and remission recorded at four or more visits was associated with an HR of 0.45 (95% CI 0.25–0.82), compared with no remission. The outcome reflects the study’s kidney risk classification combining estimated glomerular filtration rate and albuminuria categories rather than an isolated diagnosis of diabetic nephropathy. Remission was operationalized using assessments at scheduled visits; the number of qualifying visits must not be interpreted as continuously observed remission duration or as proof of the medication withdrawal interval in the 2021 consensus. Although Look AHEAD was a randomized intervention trial, achieved remission was not randomized; changes in weight, fitness, glycemia and lipid profile may confound the association.

3.4. Early Remission After Diagnosis

Morieri et al. investigated two cohorts of people with recently diagnosed T2D [12]. Cohort 1 comprised 1934 participants with follow-up up to 25 years; the reported microangiopathy association derives exclusively from cohort 2 (n = 13,277; median follow-up 4.0 years [IQR 2.0–6.3]). Remission required two HbA1c measurements < 6.5% at least 90 days apart without glucose-lowering treatment, assessed within five years of diagnosis. In cohort 2, remission versus non-remission was associated with fewer newly recorded microangiopathy events (adjusted HR 0.84, 95% CI 0.73–0.97; p = 0.019). The investigators adjusted for clinical variables significantly associated with remission; the main-text report does not provide a fully itemized covariate list for this particular complication model, so independence from weight change cannot be established from this estimate alone. Microangiopathy (retinopathy, neuropathy, CKD, or albuminuria) was exploratory and clinically recorded; incident analyses excluded prevalent disease. Mortality could not be distinguished from referral or other loss to follow-up. The difference between a significant remission association and a non-significant weight loss association is not a formal test of their difference; an incremental effect beyond weight loss remains a hypothesis.

3.5. Remission in the GLP-1 Receptor Agonist Era

GLIMPLES followed 14,141 new users of GLP-1 receptor agonists and assessed four operational remission definitions [13]. All required HbA1c < 6.5% for at least three months: definition 1 required no usual glucose-lowering pharmacotherapy; definition 2 allowed GLP-1RA alone; definition 3 allowed continuation of pre-existing therapy but no new diabetes pharmacotherapy; definition 4 allowed ongoing diabetes pharmacotherapy regardless of intensification. Remission occurred in 5.8%, 6.2%, 12.2%, and 18.3% of patients under definitions 1–4, respectively. Compared with non-remission, the adjusted microangiopathy HRs (95% CIs) reported by Fadini et al. [13] were 0.84 (0.72–0.97), 0.85 (0.74–0.99), 0.88 (0.79–0.98), and 0.95 (0.87–1.04) (Table 1), respectively. Thus, the fourth, most permissive, definition did not demonstrate a statistically clear reduction. Incident complication analyses excluded patients with the corresponding complication at baseline; the Cox models used adjustment variables described in Table 2 of the original report. Definitions 2–4 may capture sustained subdiabetic glycemia under treatment and should not be conflated with consensus-defined medication-free remission.

Table 1. Main microvascular findings, temporal eligibility, and interpretation of longitudinal reports.

Report	Exposure Timing/ Definition	Comparison and Outcome	Adjusted Estimate	Appraisal/Evidence Role
Coleman 2016 [8]	Post-surgical remission; time before relapse in relapsers	Remission vs. never; composite microvascular events	HR 0.71 (0.60–0.85); relapse subgroup per year HR 0.81 (0.67–0.99)	Direct; residual confounding; some sensitivity CIs include 1
Madsen 2019 [9]	One-year RYGB remission; metformin monotherapy with HbA1c < 6.0% permitted	Within operated: remission vs. non-remission; microvascular events	HR 0.43 (0.25–0.72)	Direct; not uniformly drug-free. Retinopathy report [15] is contextual; participant overlap not established
Hounkpatin 2021 [10]	Remission assessed years 0–2; outcomes years 2–7	Remission vs. no remission; microvascular complications	aHR 0.68 (0.62–0.74)	Direct; temporal separation; overlaps CHIA [14]
Dambha-Miller 2023 [14]	HbA1c trajectories across overlapping follow-up	Low → rising and stable low vs. persistently high; composite	aHR 0.65 (0.61–0.70); 0.59 (0.55–0.64)	Supportive only; temporal ambiguity; not drug-free remission
Gregg 2024 [11]	Visit-based remission surrogate; ≥4 positive visits ≠ continuous duration	Any remission vs. none; high-/very-high-risk CKD	HR 0.67 (0.52–0.87); ≥4 visits HR 0.45 (0.25–0.82)	Direct; postrandomization exposure, confounding
Morieri 2025 [12]	Cohort 2 n = 13,277; median follow-up 4.0 y; HbA1c < 6.5% twice ≥ 90 d apart, off therapy	Remission vs. no remission; clinically recorded new microangiopathy	aHR 0.84 (0.73–0.97)	Exploratory clinical outcome; death vs. other loss indistinguishable; outcome-specific adjustment set not fully verified
Fadini 2025 [13]	Four definitions, HbA1c < 6.5% ≥ 3 months; drug allowances differ	Remission vs. non-remission; incident microangiopathy	R1 0.84 (0.72–0.97); R2 0.85 (0.74–0.99); R3 0.88 (0.79–0.98); R4 0.95 (0.87–1.04)	Direct but definition-sensitive; exclude prevalent complication

Table 2. Structured study-level critical appraisal. Documented features are separated from plausible threats to validity.

Study Group	Documented Limitation	Potential Bias Requiring Caution
Surgical cohorts [8,9,15]	Definitions and treatment pathways differ; retinopathy remission comparison [15] is cross-sectional; overlap with [9] unverified	Confounding by weight loss, surgery response, baseline phenotype
CHIA [10,14]	Ref. [10] separates exposure and outcomes; Ref. [14] does not guarantee precedence	Reverse causality, repeated-measure selection, ascertainment
Look AHEAD [11]	Remission not randomized; visit-based exposure	Time-varying confounding, misclassification of duration
Morieri cohort 2 [12]	Exploratory clinical outcomes; death indistinguishable from loss	Informative censoring and outcome misclassification
GLIMPLES [13]	Four medication-dependent definitions; baseline complications excluded	Treatment selection, healthy responder effects

These results are definition-sensitive: progressively permissive treatment criteria increased remission frequency but attenuated the observed microangiopathy association. The 95% CI for definition 4 includes the null, and no direct causal effect of remission can be inferred. Moreover, apparent remission duration was approximately 5–6 months under definitions 1–2 and 9–10 months under definitions 3–4; these estimates are not interchangeable with the number of qualifying study visits in Look AHEAD [11,13].

4. What Can Be Inferred from the Evidence?

4.1. Consistency Is Stronger than Precision

The evidence is broadly directionally favorable but is not uniform across every operational definition, outcome or design. Temporally separated analyses, notably CHIA [10], support an association between achieved remission and lower subsequent microvascular risk. Surgical and Look AHEAD findings are also supportive, while GLIMPLES results depend on the remission definition. The overlapping-window CHIA trajectory analysis [14] is contextual rather than direct evidence of prospective remission effects. These results should not be treated as estimates of a single causal effect.

4.2. Durability May Be the Clinically Important Exposure

Several findings suggest that persistence of improved glycemia may matter, but the measures of persistence differ. Coleman reported a duration association only among people who later relapsed, with sensitivity analysis uncertainty [8]. Look AHEAD reported the number of visits meeting an epidemiological remission surrogate, not continuous time in consensus-defined remission [11]. CHIA trajectories are supportive of sustained lower glycemic exposure, but their overlap with complication ascertainment prevents secure temporal attribution [14]. Accordingly, evidence for a duration–response relation is suggestive rather than definitive; future work should record onset, relapse, cumulative time in remission and outcome-free follow-up prospectively.

4.3. Prognostic Marker Versus Disease-Modifying State

The evidence supports remission as a favorable prognostic state. Whether remission itself is disease-modifying is a harder question. A disease-modifying interpretation requires that changing the remission state changes the natural history of complications independently of the characteristics that make remission possible. Current observational analyses cannot fully establish that condition. Shorter diabetes duration, greater beta-cell reserve, lower baseline medication burden, successful weight loss, and healthier behavior all increase the probability of remission and may independently reduce complication risk.

A more plausible interpretation is that remission is both mediator and marker. Sustained lower glycemic exposure is likely to mediate part of the benefit, while the ability to achieve and maintain remission marks a more favorable metabolic phenotype and treatment response. The relative contribution of these pathways probably differs across surgery, lifestyle, and pharmacotherapy.

4.4. Why Metabolic Memory Remains Relevant

The concept of metabolic memory explains why remission can be beneficial without restoring risk to that of a person who never had diabetes. UKPDS follow-up demonstrated persistent clinical benefit from earlier glycemic separation even after HbA1c differences disappeared [5]. The experimental and translational literature describes persistent oxidative, inflammatory, epigenetic, and vascular consequences of previous metabolic exposure [6,7]. Consistent with this framework, the international remission consensus explicitly warns that classic complications may still occur after remission and recommends continued retinal, renal, foot, blood pressure, weight, and glycemic surveillance [4].

5. Organ-Specific Interpretation

5.1. Kidney Disease

Kidney disease has relatively strong organ-specific evidence because Look AHEAD defined high-/very-high-risk CKD using estimated glomerular filtration rate and urine albumin categories and found a graded association with the number of remission-positive visits [11]. The comparator was participants with no observed remission. Visit count is not continuously measured remission duration. Contemporary renal prognosis also depends on blood pressure control, renin–angiotensin system blockade and SGLT2 inhibitors; future analyses should capture these as time-varying treatments.

5.2. Retinopathy

Retinopathy evidence is less complete. It is included within composite outcomes in surgical cohorts, and the Danish retinopathy report [15] provides contextual evidence: its remission-versus-non-remission comparison was cross-sectional, while its longitudinal retinopathy change analysis compared RYGB recipients with non-operated controls. Thus, it does not independently establish a temporally ordered association between achieved remission and later retinopathy. However, rapid glycemic improvement can transiently worsen established retinopathy in susceptible patients, a concern explicitly recognized by the remission consensus [4]. This reinforces the need to distinguish prevention of incident retinopathy from progression of pre-existing disease.

5.3. Neuropathy

Neuropathy is the least well characterized of the major microvascular outcomes in remission research. It contributes to composite endpoints but rarely appears as a separately powered longitudinal outcome. The current evidence therefore does not support an organ-specific quantitative estimate for neuropathy. This gap should be stated explicitly rather than inferred from composite microvascular findings.

6. The Definition Problem in Contemporary Diabetes Care

The 2021 consensus definition provides a necessary common language but creates a practical tension in the era of cardiorenal and weight-directed pharmacotherapy. A patient may maintain HbA1c below 6.5% while continuing a GLP-1 receptor agonist for obesity or cardiovascular risk reduction or an SGLT2 inhibitor for heart failure or CKD. Under the consensus definition, remission cannot be diagnosed while usual glucose-lowering pharmacotherapy continues [4]. Yet from a prognostic perspective, such patients may occupy a markedly lower-risk glycemic state.

GLIMPLES provides empirical evidence that this is not a semantic issue: remission frequency and duration changed materially according to whether ongoing therapy was allowed [13]. Future studies should therefore report at least two clearly separated constructs: consensus-defined medication-free remission and sustained subdiabetic glycemia during ongoing disease-modifying therapy. Mixing these states under a single label risks both clinical and epidemiological misclassification.

7. Clinical Implications

The available evidence supports a cautious but clinically useful message. Remission is associated with a better subsequent microvascular prognosis, although the additional prognostic importance of remission duration remains uncertain. It should be discussed with patients as a meaningful change in disease state, not as a cure. The distinction is more than linguistic: relapse remains common, previous tissue injury may persist, and complication risk is not known to normalize.

Patients in remission should remain under active follow-up. At minimum, glycemic status should be reassessed periodically and established diabetes surveillance should continue for renal disease, retinopathy, neuropathy/foot disease, blood pressure, lipids, and weight, tailored to prior complication burden. The 2021 consensus specifically states that there is no long-term evidence supporting safe discontinuation of usual complication assessments after remission [4].

A second implication is that durability deserves explicit clinical attention. The goal should not merely be to cross the HbA1c threshold once but to sustain the metabolic changes that make remission possible. In DiRECT, remission at two years was strongly linked to maintenance of weight loss [2]. Longer or repeatedly documented remission was associated with favorable outcomes in some complication analyses, but heterogeneous duration measures and observational limitations prevent a firm duration–response conclusion.

8. Research Agenda

Future research should move beyond ever/never remission. Remission should be modeled as a time-varying exposure with explicit dates of onset and relapse, cumulative time in remission, and repeated HbA1c trajectories. Studies should distinguish incident from pre-existing microvascular disease and report kidney, retinal, and neurologic outcomes separately.

Causal inference requires particular attention. Landmark analyses, target-trial emulation, marginal structural models, and other approaches capable of handling time-varying confounding may help separate the effect of sustained lower glycemic exposure from the phenotype and treatment response that produce remission. Minimum adjustment sets should consider diabetes duration, baseline HbA1c, weight trajectory, medication exposure, renal function, blood pressure, lipids, comorbidity, socioeconomic factors, and healthcare utilization. Competing risk and informative loss to follow-up should be addressed explicitly.

Finally, the field needs a prespecified framework for pharmacotherapy-associated remission. Studies should report consensus-defined medication-free remission separately from treatment-maintained sustained subdiabetic glycemia and should examine whether the prognostic association differs by pathway to remission. The key unanswered question is no longer simply whether remission can occur but whether equal durations of remission achieved through lifestyle, surgery, or pharmacotherapy confer comparable organ protection.

9. Strengths and Limitations of the Evidence Base

The evidence base includes large longitudinal cohorts, clinically relevant endpoints, and findings from several therapeutic pathways. Its strength is greatest when remission ascertainment clearly precedes complication follow-up, as in Hounkpatin [10]. However, findings are not universally consistent across operational definitions, and apparently similar duration measures may represent distinct constructs (time before relapse, number of qualifying visits, or retrospective trajectory groups).

Several limitations constrain interpretation. Remission definitions and medication requirements differ, including metformin-permitted surgical remission [9] and GLP-1RA-permitted definitions [13]. Achieved remission is non-randomized and susceptible to baseline and time-varying confounding. In CHIA, trajectory classification can overlap outcomes [14], whereas the earlier CHIA report provides clearer temporal separation [10]. Cohort-specific missingness, surveillance differences and the handling of death are not uniformly documented; the Morieri cohort 2 could not separate death from other loss to follow-up [12]. Composite outcomes conceal organ-specific effects, and the Coleman relapse subgroup duration estimate is not robust to all sensitivity specifications [8]. Differences in follow-up and treatment also prevent a defensible common pooled effect.

This review also has limitations. It was designed as a focused critical review rather than a formal PRISMA systematic review; consequently, it should not be interpreted as an exhaustive database-level evidence synthesis. Its purpose is narrower: to evaluate the directly relevant longitudinal evidence, identify the reproducible clinical signal, and define the methodological conditions required for stronger causal inference.

10. Conclusions

Across diverse clinical settings, several longitudinal analyses associate achieved T2D remission with lower subsequent microvascular risk. The CHIA analysis with explicitly separated exposure and outcome periods provides particularly relevant temporally ordered evidence [10]; the overlapping-window trajectory analysis should instead be treated as supportive evidence about glycemic patterns [14]. Surgical, Look AHEAD and GLIMPLES findings are compatible with a favorable prognosis, but definitions, permitted medication and endpoints differ. Evidence that greater remission durability is protective is suggestive, not conclusive, because studies measure duration in non-equivalent ways.

Remission is a clinically useful prognostic descriptor, not evidence that prior diabetes-related risk is erased. The available studies do not establish an unconfounded causal effect of remission itself. Continued retinal, renal and neurologic surveillance remains warranted. Future studies should distinguish consensus-defined medication-free remission from sustained subdiabetic glycemia during treatment, separate exposure from outcome windows, and account for treatment, weight, disease phenotype, death and informative follow-up.